Department of Dermatology, Yanbian University Hospital, Yanji, China.
Department of Medical Cosmetology, Yanbian University Hospital, Yanji, China.
J Cosmet Dermatol. 2024 May;23(5):1654-1662. doi: 10.1111/jocd.16190. Epub 2024 Jan 29.
Rosacea is a prevalent chronic dermatological condition marked by facial inflammation and erythema, significantly compromising the quality of life for affected individuals. Current treatment methods for rosacea are not considered ideal because of the complex etiology of the disease. Mussel adhesive protein (MAP) is a glycoprotein derived from the foot gland of mussels. The protein exhibits anti-inflammatory properties, relieves skin itching, and promotes wound healing.
We aimed to explore the feasibility of using MAP administered via microneedle delivery for treating rosacea and the potential molecular mechanism involved.
The therapeutic effect and mechanism of MAP microneedle delivery in an LL-37-induced rosacea-like mouse model were observed using morphological and histological methods. Twenty-seven patients with erythematotelangiectatic rosacea (ETR) underwent treatment once every 1 month, with three treatments constituting one treatment course. The therapeutic effect was evaluated by comparing the clinical images taken at baseline, after the first treatment course, and after the second treatment course. The red value, CEA, and GFSS score were also calculated.
In response to the microneedle delivery of MAP, innate immunity, inflammatory infiltration, and abnormal neurovascular regulation improved significantly in rosacea-like mice. In the clinical experiments, the microneedle delivery of MAP significantly improved the symptoms of erythema, flushing, and telangiectasia in patients with ETR, and no obvious adverse reactions were observed.
MAP delivered by microneedling is effective and safe for treating ETR.
酒渣鼻是一种常见的慢性皮肤疾病，以面部炎症和红斑为特征，严重影响患者的生活质量。由于该病的病因复杂，目前的治疗方法并不理想。贻贝粘蛋白（MAP）是一种来源于贻贝足部腺体的糖蛋白。该蛋白具有抗炎、止痒和促进伤口愈合的作用。
我们旨在探讨通过微针给药的方式使用 MAP 治疗酒渣鼻的可行性及其潜在的分子机制。
采用形态学和组织学方法观察 MAP 微针给药对 LL-37 诱导的酒渣鼻样小鼠模型的治疗效果及作用机制。27 例红斑毛细血管扩张型酒渣鼻（ETR）患者接受 1 个月 1 次的治疗，3 次治疗为 1 个疗程。通过比较基线、第 1 个疗程后和第 2 个疗程后的临床图像评估治疗效果。还计算了红斑值、CEA 和 GFSS 评分。
MAP 的微针给药可显著改善酒渣鼻样小鼠的固有免疫、炎症浸润和异常的神经血管调节。在临床实验中，MAP 的微针给药显著改善了 ETR 患者的红斑、潮红和毛细血管扩张症状，且未观察到明显的不良反应。
微针给药的 MAP 治疗 ETR 有效且安全。
